Advanced Biomed Inc. Common Stock
ADVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 1.69 | -0.27 | -0.08 |
| FCF Yield | 0.00% | -0.39% | -0.13% | -1.14% |
| EV / EBITDA | 229.64 | -730.59 | -114.56 | -169.35 |
| Quality | ||||
| ROIC | -0.54% | -19.83% | -18.37% | -22.11% |
| Gross Margin | 0.00% | -12.13% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.05 | 2.58 | 81.04 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 65.53% | 42.56% | 87.58% | -1,573.75% |
| Safety | ||||
| Net Debt / EBITDA | 229.64 | 2.72 | -0.05 | 1.75 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.39 |
| Cash Conversion Cycle | -1,181.85 | -892.35 | -150,631.05 | -18,384.04 |